Health
MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers – StreetInsider.com
SAN DIEGO, April 10, 2021 /PRNewswire/ — MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer,…
SAN DIEGO, April 10, 2021 /PRNewswire/ — MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data demonstrating that voruciclib, an orally administered cyclin-dependent kinase (CDK) inhibitor that is potent against CDK9, has single agent activity against multiple KRAS mutant cancer cell lines and synergistically inhibits growth of KRAS mutant cancers in combination with KRAS inhibitors. The research is…
-
General13 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News17 hours agoWest End icon closes doors
-
General19 hours agoCalls for government to ‘get on with’ CSIRO Ginninderra Experiment Station land sale after three-year delay
-
Noosa News23 hours agoIs Auckland New Zealand’s New Cultural Capital?